Pharmacotherapy of Depression in Patients with Chronic Medical Illness
Article Sidebar
Main Article Content
Abstract
Major depressive disorder (MDD) is a psychiatric disorder which affects to public health system and lead to disability. MDD is prevalent in several medical illnesses including cardiovascular disease, stroke, cancer, Parkinson’s disease and Alzheimer disease. Evidence from clinical studies suggest that the relationship between MDD and chronic medical illness is a bidirectional relationship, moreover, depression is associated with poor prognosis of chronic medical illnesses. Therefore, appropriate treatment of depression is an important issue in depression with comorbid medical illnesses. Pharmacotherapy is the mainstay for treatment of depression. Selection of antidepressant must consider both efficacy and safety of medications in a various medical conditions in individual patient. This article will cover some of antidepressant therapy in depression with comorbid medical illnesses: treatment of depressive patients with coronary artery disease recommended selective serotonin reuptake inhibitors (SSRIs) such as sertraline and escitalopram as a first-line therapy because SSRIs showed efficacious outcomes and low risk for adverse cardiovascular events. Tricyclic antidepressants (TCAs) were associated with a significant risk for cardiovascular events. Therefore, TCAs should not use as first-line agents in depressive patients with coronary artery disease. Pharmacotherapy of depression in patients with heart failure still has limited data and conflicted results especially in large trial (SADHART-CHF and MOOD-HF study), which showed inefficacy for both depressive and cardiovascular outcomes. Pharmacotherapy of post-stroke depression (PSD) is an important strategy to improve patient outcome because appropriate use of antidepressant can reduce both depressive symptom and mortality risk. SSRIs are first-line therapy in PSD because the study showed beneficial effect and well tolerated. Treatment of depression in patients with Parkinson’s disease focused on antidepressants that increased various monoamines, therefore, TCAs (e.g. nortriptyline) that increase serotonin, norepinephrine in numerous brain areas and dopamine in prefrontal cortex may be more effective than SSRIs in these patients. However, weighed risk against benefit of TCAs in depressive patients with Parkinson’s disease especially in elderly should be consider. Pharmacotherapy of depression in patients with Alzheimer’s disease recommended SSRIs as first-line therapy and avoided antidepressants causing cognitive impairment such as TCAs and paroxetine because these drugs have anticholinergic effect. Selection of antidepressants in patients with chronic pain should use drugs that increase both norepinephrine and serotonin such as TCAs and serotonin and norepinephrine reuptake inhibitors (SNRIs) because these drugs provide benefit both depressive and pain symptoms improvement.
Article Details
In the case that some parts are used by others The author must Confirm that obtaining permission to use some of the original authors. And must attach evidence That the permission has been included
References
Aarsland D, Pahlhagen S, Ballard CG, Ehrt U, Svenningsson P. Depression in Parkinson disease-epidemiology, mechanism and management. Nat Rev Neurol 2012; 8: 35-47.
Angermann CE, Gelbrich G, Stork S, et al. Effect of escitalopram on all-cause mortality and hospitalization in patients with heart failure and depression. JAMA 2016; 315(24): 2683-93.
Arunpongpaisal S. Epidemiology of depressive disorders. In Arunpongpaisal S, Vasiknanonte S. Textbook of depressive disorders. 1st ed. Khon Kaen. 2015: 29-48.
Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2009 revision. Eur J Neurol 2010; 17(9): 1113-e88.
Banerjee S, Hellier J, Dewey M, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomized, multicentre, double-blind, placebo-controlled trial. Lancet 2011; 378: 403-11.
Draper B, Berman K. Tolerability of selective serotonin reuptake inhibitors: Issues relevant to the elderly. Drugs Aging. 2008; 25(6): 501-19.
Fan H, Yu W, Zhang Q, et al. Depression after heart failure and risk of cardiovascular and all-cause mortality: a meta-analysis. Prev Med 2014; 63: 36-42.
Garnock-Jones KP. Vortioxetine: a review of its use in major depressive disorder. CNS Drugs 2014; 28: 855-74.
Glassman AH, O’Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002; 288: 701-9.
Grippo AJ, Johnson AK. Stress, depression, and cardiovascular dysregulation: A review of neurobiological mechanisms and the integration of research from preclinical disease models. Stress 2009; 12: 1-21.
Jackson CW, Cates ME. Major depressive disorder. In Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, Kolesar JM, Dipiro JT. Pharmacotherapy: principles and practice 3rded. New York: McGrawHill. 2013: 677-93.
Jiang W, Davidson JRT. Antidepressant therapy in patients with ischemic heart disease. Am Heart J 2005: 150: 871-81.
Jorge RE, Robinson RG, Arndt S, Starkstein S, Mortality and poststroke depression: a placebo-controlled trial of antidepressants. Am J Psychiatry 2003; 160: 1823-9.
Kim JM, Bae KY, Stewart R, et al. Escitalopram treatment for depressive disorder following acute coronary syndrome; a 24-week double blind, placebo-controlled study. J Clin Psychiatry 2015; 76(1): 62-8.
Maletic V, DeMuri B. Chronic pain and depression: treatment of 2 culprits in common. Curr Psychiatr 2016; 15: 41-52.
Mann JJ. Drug therapy: The medical management of depression. N Engl J Med 2005; 353: 1819-34.
Marino S, Sessa E, Lorenzo GD, et al. Sertraline in the treatment of depressive disorders in patients with parkinson’s disease. Neurol Sci 2008; 29: 391-5.
Masi G, Brovedani P. The hippocampus, neurotrophic factors and depression. CNS Drugs. 2011; 25(11): 913-31.
Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009; 72: 886-92.
Mortensen JK, Larsson H, Johnsen HP, Andersen G. Post stroke use of selective serotonin reuptake inhibitors and clinical outcome among patients with ischemic stroke: a nationwide propensity score-matched follow-up study. Stroke 2013; 44: 420-6.
O’Connor CM, Jiang W, Kuchibhatla M, et al. Safety and efficacy of sertraline for depression in patients with heart failure. J Am Coll Cardiol 2010; 56: 692-9.
Parissis JT, Fountoulaki K, Filippatos G, Adamopoulos S, Paraskevaidis I, Kremastinos D. Depression in coronary artery disease: novel pathophysiologic mechanisms and therapeutic implications. Int J Cardiol 2007; 116: 153-60.
Ramasubbu R, Beaulieu S, Taylor VH, Schaffer A, McIntyre RS. The CANMAT task force recommendations for the management of patients with mood disorders and comorbid medical conditions: diagnostic, assessment, and treatment principles. Ann Clin Psychiatry 2012; 24(1): 82-90.
Richard IH, Mcdermott MP, Kurlan R, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012; 78: 1229-36.
Robinson RG, Jorge RE. Post-stroke depression: a review. Am J Psychiatry 2016; 173: 221-31.
Robinson RG, Spalletta G. Post-stroke depression: a review. Can J Psychiatry 2010; 55(6): 341-9.
Rudisch B, Nemeroff CB. Epidemiology of comorbid coronary artery disease and depression. Biol Psychiatry 2003; 54: 227-40.
Sahay A, Hen R. Adult hippocampal neurogenesis in depression. Nat Neurosci. 2007; 10: 1110-5.
San L, Arranz B. Agomelatine: A novel mechanism antidepressant action involving the melatonergic and serotonergic system. Eur Psychiatry. 2008; 23: 396-402.
Serebruany VL. Selective serotonin reuptake inhibitors and increased bleeding risk: Are we missing something? Am J Med 2006; 119: 113-6.
Siarkos KT, Katirtzoglou EA, Politis AM. A review of pharmacological treatments for depression in Alzheimer’s disease. J Alzheimers Dis 2015; 48: 15-34.
Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr. 2009; 14: 536-46.
Teter CJ, Kando JC, Wells BG. Major depressive disorder. In Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: a pathophysiologic approach. 10thed. New York: McGrawHill. 2017: 1041-62.
Thai Association for the Study of Pain. Clinical practice guideline for neuropathic pain. 1st ed. Bangkok. 2008.
Wong ML, Licinio J. Research and treatment approaches to depression. Nat Rev Neurosci. 2001; 2: 343-51.
Zatuska M, Dyduch A. Bupropion in the treatment of depression in parkinson’s disease. Int Psychogeriatr 2011; 23: 325-7.